[go: up one dir, main page]

HUP9903420A2 - Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections - Google Patents

Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections

Info

Publication number
HUP9903420A2
HUP9903420A2 HU9903420A HUP9903420A HUP9903420A2 HU P9903420 A2 HUP9903420 A2 HU P9903420A2 HU 9903420 A HU9903420 A HU 9903420A HU P9903420 A HUP9903420 A HU P9903420A HU P9903420 A2 HUP9903420 A2 HU P9903420A2
Authority
HU
Hungary
Prior art keywords
viral infections
preparation
fluconazole
cancers
inhibiting
Prior art date
Application number
HU9903420A
Other languages
Hungarian (hu)
Inventor
James Berger Camden
Original Assignee
The Procter & Gamble Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Application filed by The Procter & Gamble Co. filed Critical The Procter & Gamble Co.
Publication of HUP9903420A2 publication Critical patent/HUP9903420A2/en
Publication of HUP9903420A3 publication Critical patent/HUP9903420A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya a flűkőnazől felhasználása a rák, tűmőrők ésvírűsős fertőzések kezelésére alkalmazható gyógyszerkészítményelőállítására. A készítmény a flűkőnazőlt, 2-(2,4-diflűőr-fenil)-1,3-bisz(1H-1,2,4-triazől-1-il)-prőpan-2-őlt, valamint egy, a DNS-interaktív ágensek, antimetabőlitők, tűbűlin-interaktív ágensek,hőrmőnális ágensek, az aszparagináz vagy hidrőxi-karbamid-származékőkközül választőtt kemőterápiás ágens biztőnságős és hatásősmennyiségét, tővábbá valamilyen gyógyászatilag elfőgadható hőrdőzótés, adőtt esetben, egy pőtenciátőrt tartalmaz. ŕThe subject of the invention is the use of fennel oil for the production of pharmaceutical preparations for the treatment of cancer, pinworms and viral infections. The preparation consists of 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-propan-2-ol, as well as a DNA- it contains a safe and effective amount of interactive agents, antimetabolites, tübülin-interactive agents, thermal agents, a chemotherapeutic agent selected from asparaginase or hydroxycarbamide derivatives, plus some medicinally preventable heat treatment and, if appropriate, a potentiator. ŕ

HU9903420A 1995-08-04 1996-07-30 Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections HUP9903420A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections
PCT/US1996/012474 WO1997005873A2 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
HUP9903420A2 true HUP9903420A2 (en) 2000-03-28
HUP9903420A3 HUP9903420A3 (en) 2001-12-28

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903420A HUP9903420A3 (en) 1995-08-04 1996-07-30 Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections

Country Status (18)

Country Link
EP (1) EP0841921A2 (en)
JP (1) JPH11510187A (en)
KR (1) KR19990036138A (en)
CN (1) CN1195288A (en)
AR (1) AR003175A1 (en)
AU (1) AU711966B2 (en)
BR (1) BR9609966A (en)
CA (1) CA2229024A1 (en)
CZ (1) CZ33798A3 (en)
HU (1) HUP9903420A3 (en)
IL (1) IL123095A0 (en)
MX (1) MX9800998A (en)
NO (1) NO980473L (en)
NZ (2) NZ503921A (en)
PL (1) PL324904A1 (en)
SK (1) SK14198A3 (en)
TR (2) TR199800270T1 (en)
WO (1) WO1997005873A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (en) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto DRIVE UNIT COULD BE COUPLED TO A ROLLING SPEAKER AND RESULTING VEHICLE
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
PE11499A1 (en) * 1997-05-16 1999-03-01 Procter & Gamble TREATMENT OF HIV AND CANCER
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
BR9915164A (en) * 1998-11-09 2003-01-07 Idec Pharma Corp Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
EP1895012A1 (en) * 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
WO2008073961A2 (en) * 2006-12-12 2008-06-19 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2019185521A1 (en) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Ergosterol-biosynthesis inhibitor and influenza virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A3 (en) * 1985-03-29 1989-04-12 Pfizer Inc. Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5665751A (en) * 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers

Also Published As

Publication number Publication date
WO1997005873A2 (en) 1997-02-20
AR003175A1 (en) 1998-07-08
TR199801739T2 (en) 1998-12-21
EP0841921A2 (en) 1998-05-20
NO980473D0 (en) 1998-02-03
AU711966B2 (en) 1999-10-28
CA2229024A1 (en) 1997-02-20
AU6683396A (en) 1997-03-05
WO1997005873A3 (en) 1997-03-27
IL123095A0 (en) 1998-09-24
SK14198A3 (en) 1999-03-12
KR19990036138A (en) 1999-05-25
PL324904A1 (en) 1998-06-22
CZ33798A3 (en) 1998-06-17
NO980473L (en) 1998-04-03
HUP9903420A3 (en) 2001-12-28
JPH11510187A (en) 1999-09-07
MX9800998A (en) 1998-04-30
NZ503921A (en) 2002-03-01
BR9609966A (en) 1999-02-02
TR199800270T1 (en) 1998-05-21
CN1195288A (en) 1998-10-07
NZ315184A (en) 2000-05-26

Similar Documents

Publication Publication Date Title
HUP9903420A2 (en) Use of fluconazole for the preparation of pharmaceutical compositions, inhibiting the growth of cancers and treating viral infections
ES2080297T3 (en) DERIVATIVES 17-G (B)-SUBSTITUTED-4-AZA-5G (A) -ANDROSTAN-3-ONA AND PROCEDURE FOR THE PREPARATION OF THESE.
IL143512A (en) Azabicycloalkanes, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments for the prevention or treatment of infection by immunodeficiency virus
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
HUP9903506A2 (en) Use of griseofulvin for inhibiting the growth of cancers
NZ304291A (en) Trisubstituted phenyl derivatives, preparation and pharmaceutical compositions thereof
FI962952A0 (en) Delta 12,13 iso-taxol analogs their antineoplastic use and pharmaceutical compositions containing them
HUP9802629A2 (en) Use of 1,3-bis(1,2,4-triazolyl)propan-2-ol derivatives for the manufacture of pharmaceutical compositions treating cancers
BR9606547A (en) New pyrimidone derivatives with fungicidal activity
NO974696D0 (en) Pharmaceutical preparation containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibition of virus and cancer growth
DE2967005D1 (en) 2-alkoxycarbonylamino benzimidazoles having a halogen-containing substituent, their preparation and their use as parasiticides
NO980419L (en) Use of 1H, 2,4-triazole derivatives to inhibit cancer growth
NZ308391A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
WO2001066551A8 (en) Azole compounds as therapeutic agents for fungal infections
IL113743A (en) Substituted aminoalkylimidazole and triazole derivatives their preparation and pharmaceutical compositions containing them
MXPA02002007A (en) Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same.
ES8704464A1 (en) 4(5)-substituted imidazoles.
EP0178682A3 (en) 1,3-bis(1h-1,2,4-triazol-1-yl)-2-fluoro-2-(2,4-difluorophenyl)propane, antifungal composition containing it, and process for preparation of the compound and the composition
HUP9801596A3 (en) Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them
HUP9900354A3 (en) Use of condensed 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions treating and preventing diseases related with the inhibition of lipide peroxidation
MX9709530A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers.
ES2103237A1 (en) New compound derived from chromene
MX9707811A (en) A pharmaceutical composition containing n-chlorophenylcarbamates, n-chlorophenylthiocarbamates and n-phosphonoglycine derivatives for inhibiting the growth of cancers and viruses in mammals.